

Corp. Office: 1506, Chiranjiv Tower

43, Nehru Place

New Delhi - 110019

Tel.: 011-26418182, 26221811 Fax: 26213081 E-mail: srl@vsnl.com, delhi@shivalikrasayan.in

www.shavalikasayan.in CIN: L24237UR1979PLC005041

SRL/BSE/

14.06.2016

To,
The Department of Corporate Services
The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street

Sub:- Submission of Rectified Audited Financial Results (Standalone & Consolidated) of the Company for the Fourth Quarter and Year ended on 31st March, 2016 alongwith the Auditor's Report thereon

(BSE Scrip Code 539148)

Dear Sir/Madam,

Mumbai- 400001

This has reference to our earlier submission of Audited Financial Results (Standalone & Consolidated) vide transaction number 30052016309971 dated 30.05.2016 and your mail dated 13.06.2016.

We are submitting herewith the Rectified Audited Financial Results (Standalone & Consolidated) of the company for the Fourth Quarter and Year ended on 31st March, 2016 alongwith the Auditor's Report.

Due to typographical error in Consolidated Audited Financial Results for the Quarter and Year ended on March 31, 2016 at Year ended column by mistake date written as 31.12.2016 instead of 31.03.2016 and Unaudited instead of Audited.

Kindly take the same on your records and display it on your website.

Thanking you,

Your's truly for Shivalik Rasayan Limited

Priyanka Singh Company Secretary Membership No.25763 Rasay on Ltd.

Encl.: a/a



Shivalik Rasayan Ltd.

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun- 248007 CIN: L24237UR1979PLC005041

E-mail: srl@vsnl.com, www.shivalikrasayan.in

Standalone Audited Financial Results for the Quarter and year ended on March 31, 2016

PARTI

SI. No.	Particulars	Quarter ended			Year ended	
		31.03.2016 (Audited)	31.03.2015 (Audited)	31.12.2015 (Unaudited)	31.03.2016 (Audited)	31.03.2015 (Audited)
1	Income from Operations					
	(a) Net Sales/Income from Operations (Net of excise duty)	1060.81	1154.69	1073.85	4259.32	4130.0
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00
	Total income from Operations (net)	1060.81	1154.69	1073.85	4259.32	4130.0
2	Expenses	1.2				
	(a) Cost of Materials consumed	657.73	944.88	773.20	2594.83	2807.28
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-5.83	-9.79	-3.13	-2.17	-5.56
	(d) Employee benefits expense	93.62	79.23	68.24	308.74	249.65
	(e) Depreciation and amortisation expense	17.38	7.35	10.25	37.64	17.85
	(f) Other expenses (any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	124.26	81.91	129.26	872.33	795.42
	Total Expenses	887.16	1103.58	977.83	3811.37	3864.64
3	Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	173.65	. 51.11	96.02	447.96	265.41
4	Other Income	6.07	9.32	31.29	55.67	41.36
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	179.72	60.43	127.31	503.63	306.77
6	Finance Costs	58.52	33.71	20.77	104.72	34.41
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5±6)	121.20	26.72	106.54	398.91	272.36
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00
9	Profit/(Loss) from ordinary activities before tax (7±8)	121.20	26.72	106.54	398.91	272.36
10	Tax expense					
	a) Current Tax	41.74	4.62	36.22	135.91	88.35
	b) Deferred Tax	3.12	0.00	0.00	3.12	-3.33
11	Net Profit/(Loss) from ordinary activities after tax (9±10)	82.59	22.10	70.32	266.12	180.68
12	Extraordinary items (net of tax expense)	0.00	0.00	0.00	0.00	0.00
13	Net Profit/(Loss) for the period (11±12)	82.59	22.10	70.32	266.12	180.68
14	Share of Profit/(loss) of associates*	0.00	0.00	0.00	0.00	0.00
15	Minority Interest*	0.00	0.00	0.00	0.00	0.00
16	Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates (13±14±15)*		22.10	70.32	266.12	180.68
17	Paid-up equity share capital	342.00	342.00	342.00	342.00	342.00
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	1049.00	782.06	782.06	1049.00	782.06
19.i	Earnings Per Share (before extraordinary items)					
	(a) Basic	2.42	0.65	2.05		
	(b) Diluted	2.42	0.65	2.05	7.80	5.38
19.ii	Earnings Per Share (after extraordinary items)		***			
	(a) Basic	2.42	0.65	2.05	7.80	
	(b) Diluted	2.42	0.65	2.05	7.80	5.38



Notes:

- The above audited financial results have been reviewed by the Audit Committee and approved by the Board of Director's of the Company at their respective meetings held on May, 30, 2016.
- 2. The Statutory auditors of the Company have audited the above results under Regulations 33 of SEBI (LODR) Regulations, 2015
- 3. The previous periods figures have been regrouped and reclassified whereever necessary.
- 4. The company operates only in one business segment viz. Pesticides, hence segment wise reporting is not applicable.
 - * applicable in case of consolidated results.

By order of the Board of Directos for Shivalik Rasayan Limited

Rahul Bishnoi

Chairman

DIN: 00317960



Place: New Delhi Date: 30th May, 2016



Shivalik Rasayan Ltd.

CIN: L24237UR1979PLC005041

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun-248007

Standalone Statement of Assets and Liabilities

	Audited	Audited	
Particulars	As at 31.03.2016	As at 31.03.2015	
ALC: NO.	(Rs. In Lakhs)	(Rs. In Lakhs)	
A. EQUITY AND LIABILITIES			
(1) Shareholder's Funds			
(a) Share Capital	342.00	342.0	
(b) Reserves and Surplus	1049.00	782.0	
Sub-total-Shareholders' fund	1391.00	1124.0	
(2) Non-Current Liabilities	4 , 6		
(a) Long-term borrowings	775.55	40.5	
(b) Deferred tax liabilities (Net)	21.39	24.5	
(c) Long term provisions	12.35	16.0	
Sub-total-Non-current Liabilities	809.29	81.1	
(3) Current Liabilities			
(a) Short-term borrowings	90.00	0.0	
(b) Trade payables	989.12	965.6	
(c) Other current liabilities	256.54	8.6	
(d) Short-term provisions	160.24	109.2	
Sub-total-Current Liabilities	1495.91	1083.5	
TOTAL - EQUITY AND LIABILITIES	3696.20	2288.7	
3. ASSETS			
(1) Non-current assets			
(a) Fixed assets	823.85	695.9	
(b) Non-current investments	1615.70	0.0	
(c) Long term loans and advances	131.71	89.5	
(d) Other non-current assets	117.13	90.1	
Sub-total-Non-Current Assets	2688.39	875.5	
(2) Current assets			
(a) Inventories	96.79	41.6	
(b) Trade receivables	716.37	901.8	
(c) Cash and cash equivalents	64.52	433.6	
(d) Short-term loans and advances	124.75	32.9	
(e) Other current assets	5.38	3.1	
Sub-total-Current Assets	1007.81	1413.1	
TOTAL-ASSETS	3696.20	2288.77	

 Previous period/year figures have been reclassified to confirm with the current period's presentation, wherever applicable.

for Shivalik Rasayan Limited

Rasai

Place: New Delhi

Date: 30/05/2016

Rahul Bishnoi Chairman

DIN: 00317960

RAI QIMAT & ASSOCIATES

CHARTERED ACCOUNTANTS



Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of SHIVALIK RASAYAN LIMITED

We have audited the quarterly financial results of SHIVALIK RASAYAN LIMITED for the quarter ended 31st March, 2016 and the year to date results for the period 01.04.2015 to 31.03.2016 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results.

An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

 (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

 give a true and fair view of the net profit and other financial information for the quarter ended 31st March, 2016 as well as the year to date results for the period from 01.04.2015 to 31.03.2016

For Rai Qimat & Associates Chartered Accountants

(Membership Number: 80857)

Place: New Delhi Date: 30/05/2016



Shivalik Rasayan Ltd.

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun- 248007

CIN: L24237UR1979PLC005041

E-mail: srl@vsnl.com, www.shivalikrasayan.in

Consolidated Audited Financial Results for the Quarter and year ended on March 31, 2016

SI. No.	Particulars	Quarter ended		(Rs. in La	
		31.03.2016 31.03.2015		Year ended	
		(Audited)	(Audited)	31.03.2016 (Audited)	31.03.2015 (Audited)
1				()	(rauneu)
1.	Income from Operations				
	(a) Net Sales/Income from Operations (Net of excise duty)	2859.16	1154.69	10986.91	413
_	(b) Other Operating Income	0.00	0.00	0.00	- 110
-	Total income from Operations (net)	2859.16	1154.69	10986.91	413
2	Expenses				****
	(a) Cost of Materials consumed	1738.90	944.88	6698.53	280
	(b) Purchase of stock-in-trade	21.97	0.00	75.04	200
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-88.30	-9.79	99.91	
	(d) Employee benefits expense	174.70	79.23	882.63	24
	(e) Depreciation and amortisation expense	65.55	7.35	227.33	24
	(f) Other expenses (any item exceeding 10% of the total expenses	476.64	81.91	2244.23	79
	relating to continuing operations to be shown separately) Total Expenses				
3	Profit/(Loss) from operations before other income, finance costs	2389,46	1103.58	10227.66	386
4	and exceptional items (1-2) Other Income	469.70	51.11	759,26	265
5		11.28	9.32	125.70	4
	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3±4)	480.98	60.43	884.96	300
6	Finance Costs	143.53	33.71	414.86	34
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5±6)	337.45	26.72	470.10	272
8	Exceptional Items	0.00	0.00	0.00	
9	Profit/(Loss) from ordinary activities before tax (7±8)	337.45	26.72		(
10	Tax expense	0,000	20.72	470.10	272
	a) Current Tax	56.10	4.62	150.07	
	b) Deferred Tax	-17.04	0.00	150.27	88
11	Net Profit/(Loss) from ordinary activities after tax (9±10)	264.32	22.10	11.85	-3
12	Extraordinary items (net of tax expense)	0.00	0.00	307.98	180
13	Net Profit/(Loss) for the period (11+12)	264.32	22.10	0.00	0
14	Share of Profit/(loss) of associates*	0.00	0.00	307.98	180
15	Minority Interest*	0.00		0.00	0
16	Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates (13+14+15)*	264.32	0.00 22.10	0.00 307.98	180
17	Paid-up equity share capital	342.00	342.00	242.00	
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	1049.00	782.06	342.00 1049.00	342. 782.
19.i	Earnings Per Share (before extraordinary items)				
	(a) Basic	7,73	0.65	0.00	
	(b) Diluted Rasal	7.73	0.65	9.00	5.
9.ii	Earnings Per Share (after extraordinary items)	7.75	0.65	9.00	5,
	(a) Basic	7.73	0.00		
	(b) Diluted	7.73	0.65	9.00	5.3

Notes:

- 1. The above audited financial results have been reviewed by the Audit Committee and approved by the Board of Director's of the Company at their meeting held on May, 30 2016
- 2. The Statutory auditors of the Company have audited the above results under Regulations 33 of SEBI (LODR) Regulations, 2015
- 3. The Company has acquired 24.95% equity shares of Medicamen Biotech Limited on 26.02.2016 in accordance with the Share Purchase Agreement with Promoters of M/s Medicamen Biotech Limited, the Board decided to consolidate the results with respect to the Company's Associate M/s Medicamen Biotech Limited for the year ended on 31st March, 2016.
- 4. The previous periods figures have been regrouped and reclassified whereever necessary.
- 5. The company operates only in one business segment viz. pesticides, hence segment wise reporting is not applicable. * applicable in case of consolidated results.

By order of the Board of Directos for Shivalik Rasayan Limited

Rahul Bishnoi

DIN: 00317960


Chairman

2asa

Place: New Delhi Date: 30th May, 2016

FORM A (For audit report with unmodified opinion) {Pursuant to amended Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015}

١.	Name of the company	SHIVALIK RASAYAN LIMITED
2.	Annual financial statements for the year ended	31st March 2016 (Standalone)
3.	Type of Audit observation	Unqualified
1.	Frequency of observation	Not Applicable
5.	To be signed by-	
	Rahul Bishnoi (Chairman)	R. Birlim
	S. K. Singh (Managing Director)	Susceas
	Harish Pande (Chairman, Audit Committee)	
	Vinod Kumar (Chief Financial Officer)	Vinally
	Qimat Rai Garg Statutory Auditor	Okciety
		CACUAY





CIN: L24237UR1979PLC005041

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun- 248007

Consolidated Statement of Assets and Liabilities

			Audited	Audited
	Particulars		As at 31.03.2016	As at 31.03.2015
			(Rs. In Lakhs)	(Rs. In Lakhs)
١.	EQUITY AND LIABILITIES	A TOTAL OF THE REAL PROPERTY.		
(1)	Shareholder's Funds			
	(a) Share Capital	The state of the s	342.00	342.00
	(b) Reserves and Surplus	34 - A	1049.00	782.0
		Sub-total-Shareholders' fund	1391.00	1124.0
(2)	Minority Interest		175.18	0.00
(3)	Non-Current Liabilities			
(-)	(a) Long-term borrowings		1371.55	40.5
	(b) Deferred tax liabilities (Net)		95.58	24.5
	(d) Other Long term liabilities		0.00	0.00
	(c) Long term provisions		70.04	16.0
	(c) Long term provisions	Sub-total-Non-current Liabilities	1537.18	81.15
			100/110	0414
(4)	Current Liabilities		-	
	(a) Short-term borrowings		1565.96	0.0
	(b) Trade payables		2864.79	965.6
	(c) Other current liabilities		331.65	8.60
	(d) Short-term provisions		216.53	109.23
		Sub-total-Current Liabilities	4978.94	1083.54
		TOTAL - EQUITY AND LIABILITIES	8082.30	2288.77
3.	ASSETS	11-2"		
(1)	Non-current assets			
	(a) Fixed assets		2734.10	695.90
	(b) Non-current investments		0.00	0.00
	(c) Deferred tax assets (net)		0.00	0.00
	(c) Long term loans and advances	*	163.72	89.50
	(d) Other non-current assets	1	117.13	90.19
		Sub-total-Non-Current Assets	3014.94	875.59
(2)	Current assets			
(-)	(a) Current investments		2.00	0.00
	(a) Inventories		1210.55	41.60
	(b) Trade receivables		2325.74	901.80
	(c) Cash and cash equivalents		336.12	433.6
	(d) Short-term loans and advances		976.22	32.93
	(e) Other current assets		216.72	3.18
		Sub-total-Current Assets	5067.35	1413.18

1. Previous period/year figures have been reclassified to confirm with the current period's presentation, wherever applicable.

2. The Company has acquired 24.95% equity shares of Medicamen Biotech Limited on 26.02.2016 in accordance with the Share Purchase Agreement with Promoters of M/s Medicamen Biotech Limited, the Board decided to consolidate the results with respect to the Company's Associate M/s Medicamen Biotech Limited for the year ended on 31st March, 2016.

for Shivalik Rasayan Limited

Rahul Bishnoi Chairman

DIN: 00317960

Place: New Delhi Date: 30/05/2016

RAI QIMAT & ASSOCIATES

CHARTERED ACCOUNTANTS



Auditor's Report On Quarterly Consolidated Financial Results and Consolidated Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of SHIVALIK RASAYAN LIMITED

We have audited the quarterly consolidated financial results of SHIVALIK RASAYAN LIMTED for the quarter ended 31st March, 2016 and the consolidated year to date results for the period 01.04.2015 to 31.03.2016, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These consolidated quarterly financial results as well as the consolidated year to date financial results have been prepared from consolidated interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25), mandated under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India1, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We did not audit the financial statements of Medicamen Biotech Limited (Associate of Shivalik Rasayan Limited) which have been included in the consolidated quarterly financial results and consolidated year to date results, whose consolidated interim financial statements reflect total assets of Rs.60.01 Crs. as at 31.03.2016; as well as the total revenue of Rs. 67.27 as at 31.03.2016 and Rs.17.98 Crs. as at the quarter ended 31.03.2016. These interim financial statements and other financial information have been audited by other auditors whose report(s) has (have) been furnished to us, and our opinion on the quarterly financial results and the year to date results, to the extent they have been derived from such interim financial statements is based solely on the report of such other auditors.

In our opinion and to the best of our information and according to the explanations given to us these consolidated quarterly financial results as well as the consolidated year to date results:

 include the quarterly financial results and year to date of the following entities (list of entities included in consolidation);

(ii) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

RAI QIMAT & ASSOCIATES

CHARTERED ACCOUNTANTS



(iii) give a true and fair view of the consolidated net profit/lossand other financial information for the quarter ended 31st March, 2016 as well as the consolidated year to date results for the period from 01.04.2015 to 31.03.2016.

> for Rai Qimat & Associates Chartered Accountants

> > Qimat Rai Garg

(Membership Number: 80857)

Place: New Delhi Date: 30/05/2016

FORM A

(For audit report with unmodified opinion)

{Pursuant to amended Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015}

1.	Name of the company	SHIVALIK RASAYAN LIMITED
2.	Annual financial statements for the year ended	31st March 2016 (Consolidated)
3.	Type of Audit observation	Unqualified
4.	Frequency of observation	Not Applicable
5.	To be signed by-	
	Rahul Bishnoi (Chairman)	R. Bilm
	S. K. Singh (Managing Director)	Success:
	Harish Pande (Chairman, Audit Committee)	
	Vinod Kumar (Chief Financial Officer)	Vinodu
	Qimat Rai Garg Statutory Auditor	ORcihy.